Investigational agent reduces tumor resistance to breast cancer therapy

Researchers at Georgetown Lombardi Comprehensive Cancer Center have found a way to cleverly override signals that tell breast cancer cells to keep surviving in the face of anticancer treatment. The investigational agent they used renews the sensitivity of these breast cancer cells to treatment by fulvestrant (Faslodex(R)) which had stopped working.

Read the whole article on Physorg

More from Physorg